Imbalance and gait disturbance from tyrosine kinase inhibition in hepatocellular cancer.
Miksad
Rebecca A
RA
Division of Oncology, Beth Israel Deaconess Medical Center, Shapiro 9, Boston, MA 02215, USA. rmiksad@bidmc.harvard.edu
Lai
Kuan-Chi
KC
Stein
Marion C
MC
Healy
Megan E
ME
Rojas
Rafael
R
Krajewski
Katherine M
KM
Zhu
Andrew X
AX
D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects*; D006528:Carcinoma, Hepatocellular / Q000150:complications / Q000188:drug therapy*; D017326:Clinical Trials, Phase III as Topic; D020233:Gait Disorders, Neurologic / Q000139:chemically induced* / Q000503:physiopathology; D019693:Hepatitis, Autoimmune / Q000150:complications; D006801:Humans; D007211:Indoles / Q000009:adverse effects*; D008113:Liver Neoplasms / Q000150:complications / Q000188:drug therapy*; D008297:Male; D004856:Postural Balance / Q000187:drug effects*; D047428:Protein Kinase Inhibitors / Q000009:adverse effects; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors / Q000187:drug effects; D011758:Pyrroles / Q000009:adverse effects*; D012678:Sensation Disorders / Q000139:chemically induced; D000077210:Sunitinib
D000970:Antineoplastic Agents; D007211:Indoles; D047428:Protein Kinase Inhibitors; D011758:Pyrroles; D011505:Protein-Tyrosine Kinases; D000077210:Sunitinib